 |
|
Cross-sectional Analysis of a Collaborative Web-Based Database for Lupus Erythematosus–Associated Skin LesionsProspective Enrollment of 114 Patients
Siamak Moghadam-Kia, MD;
Katherine Chilek, DO;
Elizabeth Gaines, MD;
Melissa Costner, MD;
Mathew E. Rose, MB;
Joyce Okawa, RN;
Victoria P. Werth, MD
Arch Dermatol. 2009;145(3):255-260.
Objectives To assess disease severity in subsets of patients with cutaneous lupus erythematosus (CLE) by using outcome and quality-of-life measures, and to determine treatment responsiveness by establishing a Web-based database of patients with skin manifestations of lupus.
Design Prospective, cross-sectional study.
Setting University hospital cutaneous autoimmunity outpatient clinic.
Patients One hundred fourteen patients who presented from January 15, 2007, to November 8, 2007, and met the criteria for having CLE or lupus-nonspecific skin disease.
Main Outcome Measures Scores on the CLE Disease Activity and Severity Index and the modified Skindex-29 (a quality-of-life measure) completed at each visit.
Results Seven patients (6.1%) presented with acute CLE, 21 (18.4%) with subacute CLE, 77 (67.5%) with chronic CLE, 7 (6.1%) with systemic lupus erythematosus and LE-nonspecific skin lesions, and 1 (0.9%) with LE-nonspecific skin disease only. The mean baseline CLE Disease Activity and Severity Index activity/damage scores in patients with acute, subacute, and chronic CLE were 6.4/5.1, 11.1/1.6, and 7.5/10.2, respectively. The mean baseline modified Skindex-29 scores were 76.3, 79.4, and 82.7, respectively (P = .80). The disease in 11 of the patients (9.6%) was considered refractory to conventional therapies. Significantly more patients in the refractory group than the nonrefractory group were current smokers (P = .006).
Conclusion This Web-based database should allow collection of data related to disease activity, quality of life, and response to therapy at multiple centers.
Author Affiliations: Department of Dermatology, University of Pennsylvania, Philadelphia (Drs Moghadam-Kia, Chilek, Gaines, Rose, and Werth and Ms Okawa); Department of Dermatology, University of Texas (Southwestern), Dallas (Dr Costner); and Philadelphia Veterans Affairs Hospital (Dr Werth).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Clinically Relevant Information About Cutaneous Lupus Erythematosus
Jeffrey P. Callen
Arch Dermatol. 2009;145(3):316-319.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The study of Cutaneous Lupus Erythematosus Disease Area and Severity Index in Indian patients with systemic lupus erythematosus
Salphale et al.
Lupus 2011;20:1510-1517.
ABSTRACT
| FULL TEXT
Impact of Smoking in Cutaneous Lupus Erythematosus
Piette et al.
Arch Dermatol 2011;0:archdermatol.2011.342v1-6.
ABSTRACT
| FULL TEXT
Response to Antimalarial Agents in Cutaneous Lupus Erythematosus: A Prospective Analysis
Chang et al.
Arch Dermatol 2011;147:1261-1267.
ABSTRACT
| FULL TEXT
Identification and Molecular Analysis of Glycosaminoglycans in Cutaneous Lupus Erythematosus and Dermatomyositis
Chang et al.
J Histochem Cytochem 2011;59:336-345.
ABSTRACT
| FULL TEXT
Overview of common, rare and atypical manifestations of cutaneous lupus erythematosus and histopathological correlates
Obermoser et al.
Lupus 2010;19:1050-1070.
ABSTRACT
Clinical outcome measures for cutaneous lupus erythematosus
Albrecht and Werth
Lupus 2010;19:1137-1143.
ABSTRACT
Cigarette Smoking and Cutaneous Damage in Systemic Lupus Erythematosus
TURCHIN et al.
The Journal of Rheumatology 2009;36:2691-2693.
ABSTRACT
| FULL TEXT
Clinically Relevant Information About Cutaneous Lupus Erythematosus
Callen
Arch Dermatol 2009;145:316-319.
FULL TEXT
|
